MA42157A - Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent - Google Patents

Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Info

Publication number
MA42157A
MA42157A MA042157A MA42157A MA42157A MA 42157 A MA42157 A MA 42157A MA 042157 A MA042157 A MA 042157A MA 42157 A MA42157 A MA 42157A MA 42157 A MA42157 A MA 42157A
Authority
MA
Morocco
Prior art keywords
polynucleotide
salt
preparation
composition
polynucleotides
Prior art date
Application number
MA042157A
Other languages
English (en)
Inventor
Premchandran H Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MA42157A publication Critical patent/MA42157A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des aspects de la description comprennent des procédés pour la préparation d'un polynucléotide. Dans certains modes de réalisation, le procédé comprend la mise en contact d'une première composition polynucléotidique comprenant: un polynucléotide ayant une séquence de 7 sous-unités nucléosidiques ou plus et au moins deux des sous-unités nucléosidiques sont jointes par une liaison inter-sous-unité thiophosphoramidate n3 '→ p5'; et des produits synthétiques non ciblés et des réactifs; avec un sel de cation multivalent pour précipiter un sel de polynucléotide comprenant au moins un contre-ion de cation multivalent; et séparer le sel polynucléotidique de la première composition polynucléotidique mise en contact pour produire une seconde composition polynucléotidique comprenant le sel polynucléotidique. Dans certains modes de réalisation, le procédé comprend en outre la mise en contact du sel de polynucléotide avec un support de chromatographie en phase inverse; et en éluant à partir du support de chromatographie une troisième composition polynucléotidique comprenant le polynucléotide. L'invention concerne également des compositions comprenant un sel du polynucléotide comprenant au moins un contre-ion de cation multivalent.
MA042157A 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent MA42157A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
MA42157A true MA42157A (fr) 2018-02-28

Family

ID=55911083

Family Applications (2)

Application Number Title Priority Date Filing Date
MA042157A MA42157A (fr) 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
MA42569A MA42569B1 (fr) 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA42569A MA42569B1 (fr) 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Country Status (36)

Country Link
US (2) US10745687B2 (fr)
EP (1) EP3286203B1 (fr)
JP (4) JP2018513127A (fr)
KR (1) KR102401252B1 (fr)
CN (2) CN113564168B (fr)
AU (2) AU2016250576C1 (fr)
BR (1) BR112017019627B1 (fr)
CA (1) CA2978191C (fr)
CL (1) CL2017002314A1 (fr)
CO (1) CO2017009217A2 (fr)
CY (1) CY1123197T1 (fr)
DK (1) DK3286203T3 (fr)
EA (1) EA035885B1 (fr)
ES (1) ES2798270T3 (fr)
HR (1) HRP20201218T1 (fr)
HU (1) HUE051148T2 (fr)
IL (1) IL254222A0 (fr)
LT (1) LT3286203T (fr)
MA (2) MA42157A (fr)
MD (1) MD3286203T2 (fr)
ME (1) ME03811B (fr)
MX (1) MX383293B (fr)
MY (1) MY187804A (fr)
PE (2) PE20171785A1 (fr)
PH (1) PH12017501927B1 (fr)
PT (1) PT3286203T (fr)
RS (1) RS60645B1 (fr)
SA (1) SA517390103B1 (fr)
SG (2) SG11201707893RA (fr)
SI (1) SI3286203T1 (fr)
SM (1) SMT202000389T1 (fr)
TN (1) TN2017000411A1 (fr)
TW (1) TWI736532B (fr)
UA (1) UA124521C2 (fr)
WO (1) WO2016172346A1 (fr)
ZA (1) ZA201706041B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035885B1 (ru) 2015-04-23 2020-08-27 Джерон Корпорейшн Способы получения полинуклеотидов с использованием композиций солей поливалентных катионов
CA3003090A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins anticancereux
WO2018111967A1 (fr) 2016-12-13 2018-06-21 Modernatx, Inc. Purification par affinité d'arn
JP7048617B2 (ja) 2016-12-19 2022-04-05 ヴェンタナ メディカル システムズ， インク． ペプチド核酸コンジュゲート
MA49914A (fr) * 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
WO2019060522A2 (fr) * 2017-09-22 2019-03-28 The Regents Of The University Of Colorado, A Body Corporate Oligonucléotides thiomorpholino pour le traitement de la dystrophie musculaire
WO2019120635A1 (fr) 2017-12-18 2019-06-27 Ventana Medical Systems, Inc. Conjugués à base d'acide nucléique peptidique

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
EP0546055B1 (fr) 1990-08-31 1996-07-10 Regents Of The University Of Minnesota Derives de polyethylene-glycol destines a des applications en phase solide
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
CZ274596A3 (en) 1994-03-18 1997-03-12 Lynx Therapeutics Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
JP2001507229A (ja) 1996-12-20 2001-06-05 ジェロン コーポレイション テロメラーゼのｒｎａ成分を検出および阻害するための方法
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
KR100858465B1 (ko) 1999-09-10 2008-09-16 제론 코포레이션 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
JP2002060341A (ja) * 2000-08-21 2002-02-26 Terumo Corp 止血剤
EP1379689B1 (fr) 2001-03-23 2012-09-26 Geron Corporation Conjugues d'oligonucleotide
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
JP4690324B2 (ja) * 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
SI3296312T1 (sl) 2004-07-02 2021-08-31 Geron Corporation Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
CN103215248B (zh) * 2005-10-03 2016-05-18 应用生物系统有限责任公司 用于扩增核酸的组合物、方法和试剂盒
US9109015B2 (en) * 2006-11-01 2015-08-18 Biogen Ma Inc Method of isolating biomacromolecules using low pH and divalent cations
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
KR102264617B1 (ko) * 2012-06-14 2021-06-14 라이프 테크놀로지스 코포레이션 폴리머라제 연쇄 반응 (pcr)을 위한 신규 조성물, 방법 및 키트
MY180634A (en) 2012-12-07 2020-12-03 Geron Corp Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
EA035885B1 (ru) 2015-04-23 2020-08-27 Джерон Корпорейшн Способы получения полинуклеотидов с использованием композиций солей поливалентных катионов

Also Published As

Publication number Publication date
JP2018513127A (ja) 2018-05-24
IL254222A0 (en) 2017-10-31
ZA201706041B (en) 2020-11-25
MY187804A (en) 2021-10-26
EA201791753A1 (ru) 2018-04-30
PT3286203T (pt) 2020-07-08
TN2017000411A1 (en) 2019-01-16
CL2017002314A1 (es) 2018-05-04
MX2017011642A (es) 2017-11-02
CN113564168B (zh) 2024-10-25
PH12017501927B1 (en) 2022-09-02
US20160312227A1 (en) 2016-10-27
SA517390103B1 (ar) 2021-07-14
US20200339975A1 (en) 2020-10-29
TW201706284A (zh) 2017-02-16
CN107429247B (zh) 2021-08-13
SG11201707893RA (en) 2017-11-29
AU2016250576A1 (en) 2017-09-21
MX383293B (es) 2025-03-13
HRP20201218T1 (hr) 2020-12-11
CO2017009217A2 (es) 2018-02-20
CN113564168A (zh) 2021-10-29
CY1123197T1 (el) 2021-10-29
PE20171785A1 (es) 2017-12-27
ES2798270T3 (es) 2020-12-10
NZ735042A (en) 2021-11-26
JP2025061848A (ja) 2025-04-11
CN107429247A (zh) 2017-12-01
AU2016250576C1 (en) 2021-05-06
ME03811B (fr) 2021-04-20
SMT202000389T1 (it) 2020-09-10
RS60645B1 (sr) 2020-09-30
SI3286203T1 (sl) 2020-10-30
US11441144B2 (en) 2022-09-13
EP3286203A1 (fr) 2018-02-28
LT3286203T (lt) 2020-07-27
EA035885B1 (ru) 2020-08-27
BR112017019627A2 (pt) 2018-05-15
JP2022168017A (ja) 2022-11-04
TWI736532B (zh) 2021-08-21
AU2016250576B2 (en) 2021-02-04
SG10201909816PA (en) 2019-11-28
JP2021152079A (ja) 2021-09-30
MA42569B1 (fr) 2020-08-31
US10745687B2 (en) 2020-08-18
KR102401252B1 (ko) 2022-05-24
WO2016172346A1 (fr) 2016-10-27
KR20170138399A (ko) 2017-12-15
EP3286203B1 (fr) 2020-05-06
CA2978191A1 (fr) 2016-10-27
BR112017019627B1 (pt) 2022-11-29
PH12017501927A1 (en) 2018-03-05
CA2978191C (fr) 2022-10-04
MD3286203T2 (ro) 2020-08-31
UA124521C2 (uk) 2021-10-05
DK3286203T3 (da) 2020-06-02
HK1251234A1 (en) 2019-01-25
PE20221275A1 (es) 2022-09-01
HUE051148T2 (hu) 2021-03-01
AU2021202803A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MA42157A (fr) Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
da Costa et al. Geochemistry and U–Pb zircon ages of plutonic rocks from the Algodões granite-greenstone terrane, Troia Massif, northern Borborema Province, Brazil: Implications for Paleoproterozoic subduction-accretion processes
MX2017011121A (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
NZ737046A (en) Anti-cgrp antibody formulation
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
NO20084796L (no) Antagoist anti-CD40 antistoff farmasoytiske smmensetninger
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
BR112015030440A2 (pt) detecção de plano de alto desempenho com dados de câmera de profundidade
MA40882A (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
RU2014153099A (ru) Терапевтическое средство или профилактическое средство против деменции
WO2012059598A3 (fr) Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
FR2964618B1 (fr) Dispositif de solidarisation d'une lampe sur un balai d'essuyage
FR3034430A1 (fr) Lignee cellulaire surexprimant l'antigene cd303 humain
EP4389143A3 (fr) Réduction sélective de résidus de cystéine dans des anticorps il-17
MX2019003890A (es) Anticuerpos con union reducida a impurezas de proceso.
BR112014016548A2 (pt) tensoativos baseados em sulfóxido
CL2010000470A1 (es) Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo.
MA44207A (fr) Immunoglobulines conjuguées cys80
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
FR3044312B1 (fr) Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
EA201391605A1 (ru) Способы очистки вирусов с использованием гельпроникающей хроматографии
EP3793968A4 (fr) Procédé de purification d'une charge oléfinique comprenant 1234 yf
FR3016888B1 (fr) Synthetases de la colistine et cluster de genes correspondants